The p150 CAF1 Monoclonal Antibody (CAB8725) is a high-quality antibody developed for reliable detection and analysis of target proteins. This polyclonal antibody, generated in rabbits, is highly specific for human samples and has been validated for use in Western blot applications.The p150CAF-1 complex plays a crucial role in chromatin assembly and maintenance, ensuring proper DNA replication and repair processes. By targeting the p150 subunit, this antibody allows for the detection and analysis of the CAF-1 complex in various cell types, providing valuable insights into chromatin dynamics and gene regulation.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Human samples.
Product Name:
p150 CAF1 Monoclonal Antibody
SKU:
CAB8725
Size:
20μL, 100μL
Reactivity:
Human
Clone Number:
ARC2011
Conjugate:
Unconjugated
Immunogen:
Synthetic peptide. This information is considered to be commercially sensitive.
Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Synonyms:
CAF1, P150, CAF-1, CAF1B, CAF1P150, p150 CAF1
Positive Sample:
HeLa, Jurkat, SH-SY5Y
Cellular Localization:
Nucleus.
Calculated MW:
107kDa
Observed MW:
150kDa
Chromatin assembly factor I (CAF1) is a nuclear complex consisting of p50, p60 (CHAF1B; MIM 601245), and p150 (CHAF1A) subunits that assembles histone octamers onto replicating DNA in vitro (Kaufman et al., 1995 [PubMed 7600578]).
Purification Method
Affinity purification
Gene ID
10036
RRID
AB_2863595
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol and 0.05% BSA, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of various lysates using p150 CAF1 Rabbit mAb (CAB8725) at 1:1000 dilution. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 3s.
